L.M. Manso Sànchez

Hospital Universitario 12 De Octubre

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Serafín Morales

Complejo Asistencial Sótero del Río

Noelia Martínez-Jáñez

Hospital Universitario Ramón y Cajal

Brian M. Slomovitz

Mount Sinai Medical Center

Javier Cortés

Universidad Europea de Madrid

José Ignacio Chacón

Centro de Cirugía de Mínima Invasión Jesús Usón

Elsa Kalbacher

Centre Hospitalier Universitaire de Besançon

E. Whalley

Seagen (United States)

Allan Covens

Sunnybrook Health Science Centre

Taryn Cardenas

Parc de Salut

M. Teng

Icahn School of Medicine at Mount Sinai

Cooperative Institutions

GEICAM – Spanish Breast Cancer Group

Spanish Ovarian Cancer Research Group

Centro de Investigación Biomédica en Red de Cáncer

Solti

Hospital Universitario 12 De Octubre

KU Leuven

University Medical Center Hamburg-Eppendorf

Research Institute Hospital 12 de Octubre

Hospital Clínic de Barcelona

Universität Hamburg

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

6P The oncolytic virus pelareorep primes the tumor microenvironment for checkpoint blockade therapy in early breast cancer patients: Results from AWARE-1 study

Annals of Oncology (2022)

Joaquín Gavilá Gregori Houra Loghmani L.M. Manso Sànchez Ana González-Cordón Laia Paré Brunet

Atezolizumab

Clinical endpoint

Immune checkpoint

10.1016/j.annonc.2022.03.021

Cite

Citations (0)

95P PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study

Annals of Oncology (2022)

Tomás Pascual B. Bermejo De Las Heras Noelia Martínez-Jáñez Mafalda Oliveira Sònia Pernas

Lapatinib

Pertuzumab

Neoadjuvant Therapy

Taxane

10.1016/j.annonc.2022.03.111

Cite

Citations (1)

Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers

Annals of Oncology (2018)

Miguel Quintela‐Fandino L.M. Manso Sànchez Élise Martin Manuel Moreno Serafín Morales

Durvalumab

10.1093/annonc/mdy430.003

Cite

Citations (5)

234P Real-world treatment patterns and outcomes of patients receiving palbociclib plus endocrine therapy in Spain: Subgroup analysis based on age, sites and number of metastatic locations, menopausal status and dose received from PALBOSPAIN study

ESMO Open (2023)

Fernando Moreno Antón M. Bellet-Ezquerra L.M. Manso Sànchez Fernando Henao Antonio Antón Torres

PALBOSPAIN is an observational, multicenter study to evaluate real-world practice patterns and outcomes of first-line treatment for advanced breast cancer (ABC) with Palbociclib. Results from real-world progression free survival (rwPFS) and overall survival (OS) in the total population and according to endocrine sensitivity have been previously reported. Here, we provide subgroup analysis according to age, sites and number of metastatic locations, menopausal status, and dose received. Patients diagnosed with HR+/HER2- ABC who had started first-line treatment with palbociclib between November 2017 and November 2019 were included. 762 patients received Palbociclib in combination with AIs (69.4%) or fulvestrant (30.1%). Median age was 61.9 years (17.5% < 50 y; 51.8% 50-70 y; 30.7% > 70 y). 114 patients were premenopausal (15%). A total of 418 patients had visceral disease (54.9%). At baseline, patients with 1, 2-3 and >3 metastatic locations were 42.7%, 43% and 14.3% respectively. Results of real-world Response Rate (rwRR) and rwPFS are shown in the table. A total of 377 (49.5%) patients required a dose reduction. Among patients who had a first dose reduction, 164 (21.5%) required a second dose reduction. Median rwPFS was 28 months (CI 95% 25-33) in patients who had ≥ 1 dose reductions and 19 months (CI 95% 16-23) in patients who maintained the initial dose (HR 0.71; CI 95% 0.58-0.85, p=0.003). Table: 234PrwRRrwPFSCRPRSDPDN (%)N (%)N ( %)N ( %)Months CI 95%Age<5015 (11.3)50 (37.6)46 (34.6)19 (14.3)27 (21-35)50-7022 (5.6)145 (36.7)152 (38.5)57 (14.4)21 (19-26)>7013 (5.6)87 (37.2)88 (37.6)31 (13.2)27 (22-37)Menopausal statusPremenopausal13 (11.4)44 (38.6)40 (35.1)15 (13.2)27 (20-35)Postmenopausal37 (5.7)238 (36.3)246 (38)92 (14.2)24 (21-27)Visceral metastasisYes21 (7.4)17 (41.4)141 (33.7)63 (15.1)20 (18-23)No29 (8.4)109 (31.7)145 (42.2)44 (12.8)30 (25-36)Nº of locations124 (7.4)100 (30.8)136 (41.8)46 (14.2)34 (28-39)2-323 (7.0)132 (40.2)116 (35.4)47 (14.3)20 (18.24)>33 (2.8)50 (45.9)34 (31.2)14 (12.8)19 (14-24)CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not available; NR, not reached Open table in a new tab CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not available; NR, not reached Age at start of the treatment and menopausal status were not associated with PFS. Patients with visceral metastasis and >1 sites of metastasis had shorter PFS. The incidence of dose reductions was higher compared with PALOMA-2 & 3 trials. However, dose reductions did not affect Palbociclib efficacy.

Palbociclib

Fulvestrant

Subgroup analysis

10.1016/j.esmoop.2023.101422

Cite

Citations (2)

288MO InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

Annals of Oncology (2023)

Keiichi Fujiwara Brian M. Slomovitz Antonio González‐Martín Elsa Kalbacher Andrea Bagaméri

Open label

10.1016/j.annonc.2023.10.410

Cite

Citations (3)

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

Breast Cancer Research and Treatment (2024)

Noelia Martínez-Jáñez Meritxell Bellet L.M. Manso Sànchez Fernando Henao A. Anton Torres

Abstract Purpose To evaluate the efficacy and safety of first-line therapy with palbociclib in a Spanish cohort treated after palbociclib approval. Methods PALBOSPAIN is an observational, retrospective, multicenter study evaluating real-world patterns and outcomes with 1 L palbociclib in men and women (any menopausal status) with advanced HR + /HER2– BC diagnosed between November 2017 and November 2019. The primary endpoint was real-world progression-free survival (rw-PFS). Secondary endpoints included overall survival (OS), the real-world response rate (rw-RR), the clinical benefit rate, palbociclib dose reduction, and safety. Results A total of 762 patients were included. The median rw-PFS and OS were 24 months (95% CI 21–27) and 42 months (40-not estimable [NE]) in the whole population, respectively. By cohort, the median rw-PFS and OS were as follows: 28 (95% CI 23–39) and 44 (95% CI 38-NE) months in patients with de novo metastatic disease, 13 (95% CI 11–17) and 36 months (95% CI 31–41) in patients who experienced relapse < 12 months after the end of ET, and 31 months (95% CI 26–37) and not reached (NR) in patients who experienced relapse > 12 months after the end of ET. rw-PFS and OS were longer in patients with oligometastasis and only one metastatic site and those with non-visceral disease. The most frequent hematologic toxicity was neutropenia (72%; grade ≥ 3: 52.5%), and the most common non-hematologic adverse event was asthenia (38%). Conclusion These findings, consistent with those from clinical trials, support use of palbociclib plus ET as 1 L for advanced BC in the real-world setting, including pre-menopausal women and men. Trial registration number NCT04874025 (PALBOSPAIN). Date of registration: 04/30/2021 retrospectively registered.

Palbociclib

Clinical endpoint

Progression-free survival

10.1007/s10549-024-07287-w

Cite

Citations (2)

LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

Annals of Oncology (2023)

Ignace Vergote Antonio González‐Martín Keiichi Fujiwara Elsa Kalbacher Andrea Bagaméri

Open label

Open label study

10.1016/j.annonc.2023.10.029